JP2016526167A - アルツハイマー病に関する物質と方法 - Google Patents

アルツハイマー病に関する物質と方法 Download PDF

Info

Publication number
JP2016526167A
JP2016526167A JP2016517685A JP2016517685A JP2016526167A JP 2016526167 A JP2016526167 A JP 2016526167A JP 2016517685 A JP2016517685 A JP 2016517685A JP 2016517685 A JP2016517685 A JP 2016517685A JP 2016526167 A JP2016526167 A JP 2016526167A
Authority
JP
Japan
Prior art keywords
peptides
sample
group
disease
alzheimer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2016517685A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016526167A5 (enExample
Inventor
ディーター ツヒト ハンス
ディーター ツヒト ハンス
ヒューゴ ピケ イアン
ヒューゴ ピケ イアン
アンドリュー ワード マルコム
アンドリュー ワード マルコム
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Proteome Sciences PLC
Original Assignee
Electrophoretics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Electrophoretics Ltd filed Critical Electrophoretics Ltd
Publication of JP2016526167A publication Critical patent/JP2016526167A/ja
Publication of JP2016526167A5 publication Critical patent/JP2016526167A5/ja
Ceased legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/10—Signal processing, e.g. from mass spectrometry [MS] or from PCR
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/20—Supervised data analysis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2560/00—Chemical aspects of mass spectrometric analysis of biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Medical Informatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Data Mining & Analysis (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Epidemiology (AREA)
  • Evolutionary Biology (AREA)
  • Databases & Information Systems (AREA)
  • Evolutionary Computation (AREA)
  • Theoretical Computer Science (AREA)
  • Biophysics (AREA)
  • Artificial Intelligence (AREA)
  • Bioethics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Software Systems (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Signal Processing (AREA)
JP2016517685A 2013-06-07 2014-06-05 アルツハイマー病に関する物質と方法 Ceased JP2016526167A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1310203.3 2013-06-07
GBGB1310203.3A GB201310203D0 (en) 2013-06-07 2013-06-07 Materials and methods relating to Alzheimer's disease
PCT/GB2014/051741 WO2014195715A1 (en) 2013-06-07 2014-06-05 Materials and methods relating to alzheimer's disease

Publications (2)

Publication Number Publication Date
JP2016526167A true JP2016526167A (ja) 2016-09-01
JP2016526167A5 JP2016526167A5 (enExample) 2018-04-19

Family

ID=48875949

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016517685A Ceased JP2016526167A (ja) 2013-06-07 2014-06-05 アルツハイマー病に関する物質と方法

Country Status (6)

Country Link
US (1) US20160123997A1 (enExample)
EP (1) EP3004894A1 (enExample)
JP (1) JP2016526167A (enExample)
CA (1) CA2914559A1 (enExample)
GB (1) GB201310203D0 (enExample)
WO (1) WO2014195715A1 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019012671A1 (ja) * 2017-07-13 2019-01-17 株式会社Ｍｃｂｉ 認知機能障害疾患のバイオマーカーおよび該バイオマーカーを用いる認知機能障害疾患の検出方法
WO2020261608A1 (ja) * 2019-06-28 2020-12-30 株式会社島津製作所 アミロイドβの脳内蓄積状態評価方法及び評価装置
JPWO2022102654A1 (enExample) * 2020-11-10 2022-05-19
WO2022145074A1 (ja) * 2020-12-28 2022-07-07 株式会社Mcbi 判定支援情報生成方法、判定支援情報生成システム、及び情報処理装置

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201504432D0 (en) * 2015-03-17 2015-04-29 Electrophoretics Ltd Materials and methods for diagnosis and treatment of alzheimers disease
US20220260559A1 (en) * 2020-11-04 2022-08-18 Seer, Inc. Biomarkers for diagnosing alzheimer's disease

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005511063A (ja) * 2001-11-28 2005-04-28 ビオ・ビジョン・アーゲー アルツハイマー病を検出する方法およびアルツハイマー病と他の痴呆疾患とを区別する方法、関連のペプチドおよびその使用
JP2005523420A (ja) * 2001-11-23 2005-08-04 シン．クス ファーマ、インコーポレイテッド アルツハイマー病を示す補体ｃ３前駆体バイオポリマーマーカー
US20070099203A1 (en) * 2005-10-27 2007-05-03 Jing Zhang Biomarkers for neurodegenerative disorders
JP2008514946A (ja) * 2004-09-29 2008-05-08 プロティオーム・サイエンシィズ・ピーエルシー アルツハイマー病に関する方法及び組成物
JP2012132808A (ja) * 2010-12-22 2012-07-12 Mcbi:Kk 認知機能障害疾患のバイオマーカーおよび該バイオマーカーを用いる認知機能障害疾患の検出方法
JP2012515915A (ja) * 2009-01-26 2012-07-12 エレクトロフォレティクス リミテッド 方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
ATE160821T1 (de) 1990-06-11 1997-12-15 Nexstar Pharmaceuticals Inc Nukleinsäureliganden
DE60239962D1 (de) 2001-08-14 2011-06-16 Harvard College Absolute quantifizierung von proteinen und modifizierten formen davon mittels mehrstufiger massenspektrometrie
US8232066B2 (en) * 2006-07-03 2012-07-31 The Johns Hopkins University Peptide antibody depletion and its application to mass spectrometry sample preparation
EP2057465A4 (en) * 2006-08-09 2010-04-21 Homestead Clinical Corp ORGANIC PROTEINS AND METHOD OF USE THEREOF
AU2007322252A1 (en) * 2006-11-01 2008-05-29 George Mason Intellectual Properties, Inc. Biomarkers for neurological conditions
GB0704764D0 (en) 2007-03-12 2007-04-18 Electrophoretics Ltd Isobarically labelled reagents and methods of their use

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005523420A (ja) * 2001-11-23 2005-08-04 シン．クス ファーマ、インコーポレイテッド アルツハイマー病を示す補体ｃ３前駆体バイオポリマーマーカー
JP2005511063A (ja) * 2001-11-28 2005-04-28 ビオ・ビジョン・アーゲー アルツハイマー病を検出する方法およびアルツハイマー病と他の痴呆疾患とを区別する方法、関連のペプチドおよびその使用
JP2008514946A (ja) * 2004-09-29 2008-05-08 プロティオーム・サイエンシィズ・ピーエルシー アルツハイマー病に関する方法及び組成物
US20070099203A1 (en) * 2005-10-27 2007-05-03 Jing Zhang Biomarkers for neurodegenerative disorders
JP2012515915A (ja) * 2009-01-26 2012-07-12 エレクトロフォレティクス リミテッド 方法
JP2012132808A (ja) * 2010-12-22 2012-07-12 Mcbi:Kk 認知機能障害疾患のバイオマーカーおよび該バイオマーカーを用いる認知機能障害疾患の検出方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HARALD HAMPEL ET AL.: "Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives", NATURE REVIEWS. DRUG DISCOVERY, vol. 9, JPN6018008445, 2010, pages 560 - 574, ISSN: 0003754039 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019012671A1 (ja) * 2017-07-13 2019-01-17 株式会社Ｍｃｂｉ 認知機能障害疾患のバイオマーカーおよび該バイオマーカーを用いる認知機能障害疾患の検出方法
WO2020261608A1 (ja) * 2019-06-28 2020-12-30 株式会社島津製作所 アミロイドβの脳内蓄積状態評価方法及び評価装置
JPWO2022102654A1 (enExample) * 2020-11-10 2022-05-19
WO2022102654A1 (ja) * 2020-11-10 2022-05-19 株式会社Mcbi バイオマーカーの組合せ、及び、当該組合せを用いた認知機能障害又はそのリスクの検出方法
JP7737723B2 (ja) 2020-11-10 2025-09-11 株式会社Mcbi バイオマーカーの組合せ、及び、当該組合せを用いた認知機能障害又はそのリスクの検出方法
WO2022145074A1 (ja) * 2020-12-28 2022-07-07 株式会社Mcbi 判定支援情報生成方法、判定支援情報生成システム、及び情報処理装置
JP7107614B1 (ja) * 2020-12-28 2022-07-27 株式会社Mcbi 判定支援情報生成方法、判定支援情報生成システム、及び情報処理装置

Also Published As

Publication number Publication date
EP3004894A1 (en) 2016-04-13
CA2914559A1 (en) 2014-11-12
WO2014195715A1 (en) 2014-12-11
US20160123997A1 (en) 2016-05-05
GB201310203D0 (en) 2013-07-24

Similar Documents

Publication Publication Date Title
Dayon et al. Proteomics of human biological fluids for biomarker discoveries: technical advances and recent applications
Wang et al. Emerging salivary biomarkers by mass spectrometry
KR102116178B1 (ko) 간암 고위험군의 간암 발병 모니터링 또는 진단용 바이오마커 및 그 용도
Watson et al. Quantitative mass spectrometry analysis of cerebrospinal fluid protein biomarkers in Alzheimer’s disease
Korecka et al. Qualification of a surrogate matrix-based absolute quantification method for amyloid-β42 in human cerebrospinal fluid using 2D UPLC-tandem mass spectrometry
Shi et al. Advances in targeted proteomics and applications to biomedical research
Ruiz-Romero et al. Proteomics role in the search for improved diagnosis, prognosis and treatment of osteoarthritis
Fourier et al. Pre-analytical and analytical factors influencing Alzheimer's disease cerebrospinal fluid biomarker variability
US11467167B2 (en) SRM methods in Alzheimer's disease and neurological disease assays
Cilento et al. Mass spectrometry: A platform for biomarker discovery and validation for Alzheimer's and Parkinson's diseases
EP2569446B1 (en) Diagnostic markers for neuropsychiatric diseasen
Mischak et al. CE‐MS in biomarker discovery, validation, and clinical application
JP7285215B2 (ja) 大腸がんを検出するためのバイオマーカー
Gianazza et al. The selected reaction monitoring/multiple reaction monitoring-based mass spectrometry approach for the accurate quantitation of proteins: clinical applications in the cardiovascular diseases
Shao et al. Mass spectrometry-based proteomic quest for diabetes biomarkers
JP2016526167A (ja) アルツハイマー病に関する物質と方法
Fania et al. Protein signature in cerebrospinal fluid and serum of Alzheimer’s disease patients: The case of apolipoprotein A-1 proteoforms
CN111562338A (zh) 透明肾细胞癌代谢标志物在肾细胞癌早期筛查和诊断产品中的应用
WO2017153472A1 (en) Biomarker for the diagnosis of pulmonary hypertension (ph)
de Souza et al. Advances in sample preparation and HPLC–MS/MS methods for determining amyloid-β peptide in biological samples: a review
Bergman et al. Recent developments in proteomic methods and disease biomarkers
Awasthi et al. Proteomic discovery and validation of novel fluid biomarkers for improved patient selection and prediction of clinical outcomes in Alzheimer’s disease patient cohorts
Yang et al. An alpha‐synuclein MRM assay with diagnostic potential for Parkinson's disease and monitoring disease progression
WO2015020523A1 (en) Biomarkers for early diagnosis of alzheimer's disease
Blonder et al. Proteomic biomarker discovery: it's more than just mass spectrometry

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160219

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170602

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170607

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180309

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180313

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180522

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20181120

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20190326